George de Urioste - 02 Oct 2026 Form 4 Insider Report for HeartBeam, Inc. (BEAT)

Reporting relationship: Director
Issuer ticker: BEAT
Reported as of: 02 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Oct 2026, 16:21:10 UTC
Prior SEC filing: 23 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ George de Urioste

Key filing fact

George de Urioste filed Form 4 for HeartBeam, Inc. (BEAT) on 09 Oct 2026.

Key facts

This page summarizes George de Urioste's Form 4 filing for HeartBeam, Inc. (BEAT).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 09 Oct 2026, 16:21.

Change

Previous filing in this sequence was filed on 23 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001270068 Primary reporting owner

de Urioste George

Relationship: Director
Address: 2118 WALSH AVENUE, SUITE 210, SANTA CLARA
Signature: /s/ George de Urioste
Signature date: 09 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BEAT transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +93,750
Change %
Price: $0.000000^*
Shares after: 93,750
Date: 02 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 93,750
Exercise price
Footnotes: F1, F2

BEAT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +93,750
Change %
Price: $0.000000^*
Shares after: 93,750
Date: 02 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 93,750
Exercise price: $0.4350
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon settlement.

Footnote F2

The RSUs were granted on October 2, 2026 under the Issuer's 2022 Equity Incentive Plan, as amended (the "Plan"), as an annual RSU award to non-employee directors. One hundred percent (100%) of the RSUs will vest on the earlier of October 2, 2027 or the date of the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service as a non-employee director through the vesting date. Vested RSUs will be settled in shares of common stock. RSUs do not expire.

Footnote F3

The stock option was granted on October 2, 2026 under the Plan. The option vests as to one-half (1/2) of the underlying shares on the grant date, and as to the remaining one-half (1/2) on January 1, 2027, subject to the Reporting Person's continued service as a non-employee director through the applicable vesting date, with full acceleration of any then-unvested shares immediately prior to a Change in Control (as defined in the Plan).